RE:RE:RE:Ok I was said by mangement, that being long before the recent pancreatic cancer opportunity, They would not even consider anything not starting with a $B
aka minium bilkion dollars.
For those who recall, that was on the heals of an O.V. Company from Australia bought out for just around $500 million.
All the others were in the $1-$billion range...( that was around 2016).
Since then pages of reports & buyouts have happened.
Some with great results for the aquiring company, some resulted in failures.
Moving to today.
Notable has given ample evidence of the marketplace being $3B to $5billion.
Onc as far as we know.
1. working towards phase 3 MBc & pancreatic cancer phase 3; in both examples they need a significant business deal.
2. The FDA meeting results & bracelet O.S. Could be the required data to close the negotiations/ discussions etc.
Partneship ? Buyout? Other financial re- organization? Anything is possible.
To get announce phase 3 start dates & parameters, costs very little.
However with those questions answered.
" what does MBc phase 3 trial entail" ? " where does Roche sit within the pancreatic cancer phase 3"?
THEN , Onc has a much stronger negotiating position.